These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

147 related items for PubMed ID: 22259876

  • 1. New hepatitis C regimen stimulates changes in therapy management.
    Reinke T.
    Manag Care; 2011 Dec; 20(12):41-2. PubMed ID: 22259876
    [No Abstract] [Full Text] [Related]

  • 2. Infectious diseases. First specific drugs raise hopes for hepatitis C.
    Enserink M.
    Science; 2011 Apr 08; 332(6026):159-60. PubMed ID: 21474720
    [No Abstract] [Full Text] [Related]

  • 3. [A new era in therapy of hepatitis C: "the therapy can now be individualized" (interview by Dr. med. Dirk Einecke)].
    Manns M.
    MMW Fortschr Med; 2011 Jul 21; 153(29-31):17. PubMed ID: 21830729
    [No Abstract] [Full Text] [Related]

  • 4. Viral hepatitis C in 2014--the beginning of the end?
    Prelipcean CC, Gogălniceanu P, Mihai C.
    Rev Med Chir Soc Med Nat Iasi; 2014 Jul 21; 118(2):272-8. PubMed ID: 25076687
    [No Abstract] [Full Text] [Related]

  • 5. Prompt arrival of antivirals against hepatitis C for HIV patients.
    Barreiro P, Vispo E.
    AIDS Rev; 2010 Jul 21; 12(4):242-3. PubMed ID: 21344779
    [No Abstract] [Full Text] [Related]

  • 6. [Future of antiviral therapy for chronic hepatitis C. Direct antiviral acting medications].
    Lange CM, Sarrazin C, Zeuzem S.
    Pharm Unserer Zeit; 2011 Jan 21; 40(1):60-7. PubMed ID: 21194084
    [No Abstract] [Full Text] [Related]

  • 7. [Therapy of hepatitis C: new inhibitors as hammers against HCV].
    Bublak R.
    MMW Fortschr Med; 2013 Jun 13; 155 Suppl 1():10-1. PubMed ID: 23961643
    [No Abstract] [Full Text] [Related]

  • 8. Excitement grows for potential revolution in hepatitis C virus treatment.
    Opar A.
    Nat Rev Drug Discov; 2010 Jul 13; 9(7):501-3. PubMed ID: 20592732
    [No Abstract] [Full Text] [Related]

  • 9. Telaprevir, boceprevir, cytochrome P450 and immunosuppressive agents--a potentially lethal cocktail.
    Charlton M.
    Hepatology; 2011 Jul 13; 54(1):3-5. PubMed ID: 21710471
    [No Abstract] [Full Text] [Related]

  • 10. [New times for the treatment of chronic hepatitis C].
    Gerstoft J, Fomsgaard A.
    Ugeskr Laeger; 2012 Mar 19; 174(12):795. PubMed ID: 22433552
    [No Abstract] [Full Text] [Related]

  • 11. [Boceprevir and telaprevir: clinical efficacy, safety and drug-drug interactions].
    Nikitin AV.
    Antibiot Khimioter; 2012 Mar 19; 57(9-10):47-9. PubMed ID: 23477220
    [No Abstract] [Full Text] [Related]

  • 12. Economic evaluation of direct-acting antiviral therapy in chronic hepatitis C.
    Gellad ZF, Reed SD, Muir AJ.
    Antivir Ther; 2012 Mar 19; 17(6 Pt B):1189-99. PubMed ID: 23186646
    [Abstract] [Full Text] [Related]

  • 13. Update on the use of direct-acting antiviral agents for the treatment of chronic hepatitis C virus infection.
    Fernández-Yunquera A, Rincón D, Salcedo M, Bañares R.
    Rev Esp Quimioter; 2013 Sep 19; 26(3):189-92. PubMed ID: 24080883
    [No Abstract] [Full Text] [Related]

  • 14. Protease inhibitors for treatment of genotype 1 hepatitis C virus infection.
    Rowe IA, Mutimer DJ.
    BMJ; 2011 Nov 10; 343():d6972. PubMed ID: 22074942
    [No Abstract] [Full Text] [Related]

  • 15. New Merck and Vertex drugs raise standard of care in hepatitis C.
    Sheridan C.
    Nat Biotechnol; 2011 Jul 11; 29(7):553-4. PubMed ID: 21747363
    [No Abstract] [Full Text] [Related]

  • 16. [Hepatitis C update: what has changed? What can we expect in the near future?].
    Geier A.
    MMW Fortschr Med; 2013 Nov 07; 155(19):59-62. PubMed ID: 24475674
    [No Abstract] [Full Text] [Related]

  • 17. Directly acting antivirals for hepatitis C and antiretrovirals: potential for drug-drug interactions.
    Seden K, Back D.
    Curr Opin HIV AIDS; 2011 Nov 07; 6(6):514-26. PubMed ID: 22001895
    [Abstract] [Full Text] [Related]

  • 18. Protease inhibitors in hepatitis C: from chronic disease to cure.
    Iqbal M, McCormick PA.
    Ir Med J; 2011 Sep 07; 104(8):230-1. PubMed ID: 22125874
    [No Abstract] [Full Text] [Related]

  • 19. [Victrelis and Incivek against hepatitis C: some promising options].
    Sabourin G.
    Perspect Infirm; 2012 Sep 07; 9(1):58-9. PubMed ID: 22295460
    [No Abstract] [Full Text] [Related]

  • 20. The cost-effectiveness of boceprevir for hepatitis C.
    Neoh CF, Kong DC.
    Expert Rev Pharmacoecon Outcomes Res; 2014 Jun 07; 14(3):319-34. PubMed ID: 24708054
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.